Prognostic value of CD99, CD117, p53 and bcl-2 in Ewing sarcoma family tumours

European Journal of Oncology

Volumn 12, Issue 4, 2007, Pages 243-253

  Kavalar, Rajko ^a   Marinšek, Živa Pohar ^b   Jereb, Berta ^b   Čagran, Branka ^c   Golouh, Rastko ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

Ewing sarcoma family tumours (ESFT); Immunohistochemistry; Prognostic factors; Survival analysis; Tissue array method

Indexed keywords

CD99 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PROTEIN BCL 2; PROTEIN P53; STEM CELL FACTOR RECEPTOR; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOGENETICS; EWING SARCOMA; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; PRIMARY TUMOR; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTO ONCOGENE; RISK ASSESSMENT; SURVIVAL; TISSUE MICROARRAY;

EID: 38949192496     PISSN: 11286598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Paulussen M, Ahrens S, Dunst AJ, et al. Localised Ewing tumor of bone: final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol 2001; 19: 1818-29.
2. Folpe AL, Hill CE, Parham DM, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol 2000; 24: 1657-62.
3. De Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16: 1248-55.
4. De Alava E, Pardo J. Ewing tumor: tumor biology and clinical applications. Int J Surg Pathol 2001; 9: 7-17.
5. Franchi A, Pasquinelli G, Cenacchi G, et al. Immunohistochemical and ultrastructural investigation of neural differentiation in Ewing sarcoma/PNET of bone and soft tissues. Ultrastruct Pathol 2001; 25: 219-25.
6. Llombart-Bosch A, Navarro S. Immunohistochemical detection of EWS and FLI-1 proteins in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. App Immunohistochem Mol Morphol 2001; 9: 255-60.
7. Harms D. Soft tissue sarcoma in the Kiel Pediatric Tumour Registry. Curr Top Pathol 1995; 89: 31-45.
8. Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997; 44: 991-1004.
9. Hartman KR, Triche TJ, Kinsella TJ, et al. Prognostic value of histopathology in Ewing's sarcoma. Long-term follow-up of distal extremity primary tumors. Cancer 1991; 67: 163-71.
10. Parham DM, Hijazi Y, Steinberg SM, et al. Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol 1999; 30: 911-8.
11. Devoe K, Weidner N. Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol 2000; 17: 216-24.
12. Gerald WL. A practical approach to the differential diagnosis of small round cell tumors of infancy using recent scientific and technical advances. Int J Surg Pathol 2000; 87: 87-97.
13. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma. Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001; 23: 99-104.
14. Sandberg AA, Bridge JA. Updates on cytogenetic and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet 2000; 123: 1-26.
15. Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol 2003; 56: 96-102.
16. De Alava E, Lozano MD, Patino A, et al. Ewing family tumors: potential prognostic value of reverse transcriptase polymerase chain reaction detection of minimal residual disease in peripheral disease in peripheral blood samples. Diagn Mol Pathol 1998; 7: 152-7.
17. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003; 21: 85-91.
18. Sumeraurer D, Vicha A, Kucerova H, et al. Detection of minimal marrow infiltration in patients with localized and metastatic Ewing sarcoma using RT-PCR. Folia Biol (Praha) 2001; 47: 206-10.
19. Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Pediatr Drugs 2002; 4: 21-8.
20. De Alava E, Antonescu CR, Panizo A, et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer 2000; 89: 783-92.
21. Dunst J, Ahrens S, Paulussen M, et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998; 42: 379-84.
22. Frisk P, Stalberg E, Stromberg B, et al. Painful peripheral neuropathy after treatment with high-dose ifosfamide. Med Pediatr Oncol 2001; 37: 379-82.
23. Lilje C, Sauter S, Hinkelbein W, et al. Severe neuropathy after chemo-and radiotherapy of Ewing sarcoma. Klin Pädiatr 1995; 207: 204-6.
24. Marinšek ŽP, Kavalar R, Jereb B. Ewing sarcoma/PNET: 27 years of experience in Slovenia. Pediatr Hematol Oncol 2006; 23(4): 355-67.
25. Rossbach HC, Chamizo W, Walling AK, et al. Ki-1 large-cell anaplastic lymphoma after Ewing sarcoma. J Pediatr Hematol Oncol 2002; 21(1): 50-2.
26. Abudu A, Mangham DC, Reynolds GM, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer 1999; 79: 1185-9.
27. Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1(IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001; 92: 2941-7.
28. Tsokos M, Steinberg SM, Stocker DM, et al. Bcl2 may be predictive of survival in patients with peripheral primitive neuroectodermal tumors (PNET). Mod Pathol 1995; 8: 145A.
29. Perri T, Fogel M, Mor S, et al. Effect of P-glycoprotein expression on outcome in the Ewing family of tumors. Pediatr Hematol Oncol 2001; 18: 325-40.
30. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005; 41(9): 1349-61.
31. Ahmed A, Gilbert-Barness E, Lascon A. Expression of c-kit in Ewing family of tumors; a comparison of different immunohistochemical protocols. Pediatr Dev Pathol 2004; 7: 342-7.
32. Smithey BE, Pappo AS, Hill DA. C-kit expression in pediatric solid tumors. Am J Surg Pathol 2002; 26: 486-92.
33. MIC2. Am J Pathol 1991; 139: 317-25.
34. Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody 013: antibody that recognized glycoprotein p30/32 MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994; 18: 486-94.
35. Scotlandi K, Manara MC, Strammiello R, et al. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003; 21: 1952-60.
36. Galli SJ, Zsebo KM, Geissler EN. The kit ligand stem cell factor. Adv Immunol 1994; 55: 1-96.
37. Hirota S, Nishida T, Isozaki K, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J Pathol 2001; 193: 505-10.
38. Landuzzi L, De Giovanni C, Nicoletti G, et al. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol 2000; 157: 2123-31.
39. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13: 1134-42.
40. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol 2000; 13: 536-41.
41. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991; 6: 2291-6.
42. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726-7.
43. Kitamura Y, Hirota S, Nishida T. A loss-of-function mutation of c-kit results in depletion of mast cells and interstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis. Mutat Res 2001; 477: 165-71.
44. Lai R, Arber DA, Chang KL, et al. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol 1998; 11: 864-9.
45. Lane DP. A death in the life of p53. Nature 1993; 362: 786-7.
46. Mangham DC, Cannon A, Li XQ, et al. p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumours is an uncommon event. J Clin Mol Pathol 1995; 48: M79-M82.
47. Rosen G, Caparros B, Nirenberg A, et al. Ewing's sarcoma: ten-year experience with adjuvant chemotherapy. Cancer 1981; 47: 2204-13.
48. Moch H, Kononen J, Kallioniemi OP, et al. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Mod Pathol 2001; 8: 14-20.
49. Packeisen J, Buerger H, Krech R, et al. Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol 2002; 55: 613-5.
50. Cox DR, Oakes D. Analysis of survival data. New York: Chapman & Hall, 1984.
51. Nocito A, Kononen J, Kallioniemi OP, et al. Tissue microarrays (TMAS) for high-troughput molecular pathology research. Int J Cancer 2001; 94: 1-5.
52. Hornick JL, Fletcher CDM. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188-93.
53. Issakov J, Amir G, Meller I, et al. Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: correlation with clinical outcome. Hum Pathol 2002; 33(2): 170-4.
54. Llombart-Bosch A, Contesso G, Henry-Amar M, et al. Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations. Virchows Arch 1986; 409: 627-40.
55. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing's sarcoma study group. J Clin Oncol 2000; 18: 3108-14.